Form D · Biotechnology
EtiraRX, Inc.
Dallas, TX · CIK 0001996442
Offering snapshot reported May 14, 2026 · SEC filing
- Reported sold
- $2.28M Offering amount: $3M
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 17, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 14, 2026 | Initial | $2,277,533 | No comparison | 21 | SEC filing |
| Jun 23, 2025 | Initial | $2,399,987 | No comparison | 3 | SEC filing |
| Oct 5, 2023 | Initial | $4,820,140 | No comparison | 34 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-583961
Source: Form D, filed May 14, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Russell Hayward | Director, Executive |
| Annalisa Jenkins | Director |
| Ganesh Raj | Director, Executive |
| Justin Stebbing | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3060 Pegasus Park Drive Building 6
Dallas, TX, 75247
Dallas, TX, 75247